Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker GILD · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Study of GS-2426 in Participants With Advanced Solid Tumors NCT07601243 · Advanced Solid Tumors GS-2426 | GILD Gilead Sciences | Phase 1 | Recruiting | 174 | Jan 2029 | Registry ↗ |
| Nov 12, 2026 | Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors NCT06167317 · Advanced Solid Tumors GS-0201, Sacituzumab Govitecan | GILD Gilead Sciences | Phase 1 | Recruiting | 278 | Sep 2028 | Registry ↗ |
| Nov 12, 2026 | Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory La… NCT05459571 · Relapsed or Refractory Large B-cell Lymphoma Axicabtagene Ciloleucel, Cyclophosphamide | GILD Kite, A Gilead Company | Phase 2 | Completed | 35 | Nov 24, 2025 | Registry ↗ |
| Nov 12, 2026 | Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Vir… NCT02932150 · Chronic Hepatitis B TAF, Placebo | GILD Gilead Sciences | Phase 2 | Active, not recruiting | 150 | Oct 27, 2026 | Registry ↗ |
| Nov 10, 2026 | Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HI… NCT07708727 · HIV-1-infection GS-3242 Tablet, GS-3242 Injection | GILD Gilead Sciences | Phase 2/3 | Recruiting | 700 | Oct 2030 | Registry ↗ |
| Nov 10, 2026 | A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed Peop… NCT07645287 · HIV-1-infection GS-3242 Tablet, GS-3242 Injection | GILD Gilead Sciences | Phase 2 | Recruiting | 175 | Aug 2027 | Registry ↗ |
| Nov 10, 2026 | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastati… NCT07546812 · HER2-negative, Gastroesophageal Junction Denikitug, Nivolumab | GILD Gilead Sciences | Phase 2 | Active, not recruiting was recruiting | 120 | Jan 2030 | Registry ↗ |
| Nov 6, 2026 | A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Cl… NCT06337032 · HIV-1-infection F/TAF (High Dose Tablet), F/TAF (Low Dose Tablet) | GILD Gilead Sciences | Phase 4 | Recruiting | 350 | Jun 2027 | Registry ↗ |
| Nov 5, 2026 | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Succes… NCT06333808 · HIV-1-infection Bictegravir/Lenacapavir (BIC/LEN) FDC, Lenacapavir | GILD Gilead Sciences | Phase 3 | Active, not recruiting | 577 | Oct 27, 2025 | Registry ↗ |
| Nov 5, 2026 | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Succes… NCT05502341 · HIV-1-infection Bictegravir, Lenacapavir | GILD Gilead Sciences | Phase 2/3 | Active, not recruiting | 689 | Sep 29, 2025 | Registry ↗ |
| Nov 4, 2026 | A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors NCT07703878 · Solid Tumor GS-1206 | GILD Gilead Sciences | Phase 1 | Recruiting | 302 | Sep 2029 | Registry ↗ |
| Nov 4, 2026 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Pat… NCT05633654 · Triple Negative Breast Cancer Sacituzumab govitecan-hziy (SG), Pembrolizumab | GILD Gilead Sciences | Phase 3 | Recruiting | 1,514 | Jun 2027 | Registry ↗ |
| Nov 3, 2026 | Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Geni… NCT07912996 · HSV-2 Infection GS-1179, GS-1179 PTM | GILD Gilead Sciences | Phase 2 | Not yet recruiting | 300 | Nov 2027 | Registry ↗ |
| Nov 3, 2026 | FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or… NCT06303505 · Ovarian Cancer, Non-small Cell Lung Cancer TUB-040, Bevacizumab | GILD Gilead Sciences | Phase 1/2 | Recruiting | 334 | Dec 2027 | Registry ↗ |
| Nov 2, 2026 | Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV NCT07908446 · HIV-1 Infection BIC/LEN FDC, Lenacapavir | GILD Gilead Sciences | Phase 4 | Not yet recruiting | 400 | Jul 2028 | Registry ↗ |
| Nov 2, 2026 | Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis NCT06051617 · Primary Biliary Cholangitis Seladelpar, Placebo | GILD Gilead Sciences | Phase 3 | Recruiting | 402 | Aug 2030 | Registry ↗ |
| Nov 2, 2026 | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucab… NCT05776134 · Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia Brexucabtagene Autoleucel | GILD Kite, A Gilead Company | — | Available | — | — | Registry ↗ |
| Oct 29, 2026 | To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant… NCT07903506 · Newly Diagnosed Multiple Myeloma Anitocabtagene Autoleucel, Isatuximab | GILD Kite, A Gilead Company | Phase 3 | Not yet recruiting | 750 | Mar 2039 | Registry ↗ |
| Oct 28, 2026 | Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma NCT04989803 · Relapsed and/or Refractory B-cell Lymphoma Cyclophosphamide, Fludarabine | GILD Kite, A Gilead Company | Phase 1/2 | Active, not recruiting | 247 | Feb 2030 | Registry ↗ |
| Oct 27, 2026 | Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis NCT07841977 · Primary Biliary Cholangitis Seladelpar, PTM Seladelpar | GILD Gilead Sciences | Phase 2 | Recruiting | 132 | Dec 2028 | Registry ↗ |
| Oct 26, 2026 | Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relap… NCT07479797 · Relapsed or Refractory Large B-cell Lymphoma KITE-753, Axicabtagene Ciloleucel | GILD Kite, A Gilead Company | Phase 3 | Active, not recruiting | 550 | May 2031 | Registry ↗ |
| Oct 23, 2026 | Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undet… NCT07841990 · HIV-1 Infection B/F/TAF, GS-3242 | GILD Gilead Sciences | Phase 2 | Recruiting | 125 | Aug 2027 | Registry ↗ |
| Oct 23, 2026 | Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors NCT07128303 · Advanced Solid Tumor GS-5319, Carboplatin | GILD Gilead Sciences | Phase 1 | Recruiting | 476 | May 2028 | Registry ↗ |
| Oct 22, 2026 | Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases NCT06626919 · Muscular Diseases, Neuromuscular Manifestations anito-cel, Cyclophosphamide | GILD Kite, A Gilead Company | Phase 1 | Recruiting | 30 | Oct 2028 | Registry ↗ |
| Oct 22, 2026 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometr… NCT06486441 · Endometrial Cancer Sacituzumab govitecan-hziy, Doxorubicin | GILD Gilead Sciences | Phase 3 | Active, not recruiting | 640 | Jun 2029 | Registry ↗ |
| Oct 21, 2026 | A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in New… NCT07887672 · Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab | GILD Kite, A Gilead Company | Phase 3 | Not yet recruiting | 600 | Feb 2042 | Registry ↗ |
| Oct 21, 2026 | Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention NCT07473778 · HIV Infections Lenacapavir Injection, Emtricitabine/tenofovir disoproxil f… | GILD Gilead Sciences | — | Recruiting | 3,000 | Apr 2028 | Registry ↗ |
| Oct 20, 2026 | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Adva… NCT07527858 · Advanced Microsatellite Stable Colorectal Cancer Denikitug, Nivolumab | GILD Gilead Sciences | Phase 2 | Recruiting | 170 | Dec 2028 | Registry ↗ |
| Oct 20, 2026 | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Exte… NCT06801834 · Extensive Stage Small Cell Lung Cancer (ES-SCLC) Sacituzumab Govitecan (SG), Topotecan | GILD Gilead Sciences | Phase 3 | Recruiting | 695 | Oct 2029 | Registry ↗ |
| Oct 19, 2026 | Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual… NCT07304154 · Chronic Inflammatory Demyelinating Polyneuropathy, Myasthen… KITE-363, Fludarabine | GILD Kite, A Gilead Company | Phase 1 | Recruiting | 57 | Jun 2029 | Registry ↗ |
| Oct 16, 2026 | Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent… NCT04994509 · Pre-Exposure Prophylaxis of HIV Infection Oral Lenacapavir (LEN), Subcutaneous (SC) Lenacapavir (LEN) | GILD Gilead Sciences | Phase 3 | Active, not recruiting | 5,368 | May 27, 2024 | Registry ↗ |
| Oct 6, 2026 | Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants… NCT06562907 · Weight Management GS-4571, Placebo | GILD Gilead Sciences | Phase 1 | Recruiting | 134 | Feb 2027 | Registry ↗ |
| Oct 6, 2026 | Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men,… NCT04925752 · Pre-Exposure Prophylaxis of HIV Infection Oral Lenacapavir (LEN), F/TDF | GILD Gilead Sciences | Phase 3 | Active, not recruiting | 3,292 | Aug 21, 2024 | Registry ↗ |
| Oct 2, 2026 | Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leu… NCT05457010 · Acute Myeloid Leukemia, Myelodysplastic Syndromes SPRX002, ARC-T Cells | GILD Kite, A Gilead Company | Phase 1 | Active, not recruiting | 24 | Oct 2026 | Registry ↗ |
| Oct 1, 2026 | Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized… NCT04150068 · HIV-1-infection Oral Lenacapavir, Oral Lenacapavir Placebo | GILD Gilead Sciences | Phase 2/3 | Active, not recruiting | 72 | Oct 5, 2020 | Registry ↗ |
| Sep 29, 2026 | Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 NCT06532656 · HIV-1-infection Lenacapavir, Bictegravir/Lenacapavir (BIC/LEN) FDC | GILD Gilead Sciences | Phase 2/3 | Active, not recruiting | 75 | Jul 2030 | Registry ↗ |
| Sep 28, 2026 | A Study of KITE-363 in Participants With Refractory Autoimmune Diseases NCT07038447 · Systemic Lupus Erythematosus, Lupus Nephritis KITE-363, Fludarabine | GILD Kite, A Gilead Company | Phase 1 | Enrolling by invitation | 52 | Sep 2030 | Registry ↗ |
| Sep 24, 2026 | Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and… NCT02881320 · HIV-1 Infection B/F/TAF (Adult Strength), B/F/TAF (Low Dose) | GILD Gilead Sciences | Phase 2/3 | Active, not recruiting | 177 | Mar 24, 2025 | Registry ↗ |
| Sep 23, 2026 | Study of GS-0415 and How It Works in People With HIV NCT07719491 · HIV -1 Infection GS-0415, GS-0415 Placebo | GILD Gilead Sciences | Phase 1 | Recruiting | 112 | Aug 2029 | Registry ↗ |
| Sep 21, 2026 | Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies NCT05041309 · Solid and Hematological Malignancies, Autoimmune Diseases Axicabtagene Ciloleucel, Brexucabtagene Autoleucel | GILD Kite, A Gilead Company | — | Enrolling by invitation | 1,500 | Dec 2040 | Registry ↗ |
| Sep 18, 2026 | Study of Bulevirtide in Participants With Chronic Hepatitis D Infection NCT05718700 · Chronic Hepatitis D Infection Bulevirtide | GILD Gilead Sciences | — | Terminated | 170 | Aug 31, 2026 | Registry ↗ |
| Sep 18, 2026 | Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in… NCT02252835 · Gout, Hyperuricemia Arhalofenate, Febuxostat | GILD Gilead Sciences | Phase 2 | Completed | 32 | Dec 2014 | Registry ↗ |
| Sep 18, 2026 | Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout NCT01336686 · Hyperuricemia, Gout Arhalofenate, Arhalofenate | GILD Gilead Sciences | Phase 2 | Completed | 67 | Nov 2011 | Registry ↗ |
| Sep 18, 2026 | Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered… NCT01035879 · Diabetes MBX-2982, MBX-2982 | GILD Gilead Sciences | Phase 2 | Completed | 100 | Aug 2010 | Registry ↗ |
| Sep 18, 2026 | Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control… NCT00814372 · Type 2 Diabetes Mellitus MBX-102, Placebo | GILD Gilead Sciences | Phase 2 | Terminated | 242 | Feb 2010 | Registry ↗ |
| Sep 17, 2026 | Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors NCT05007782 · Advanced Solid Tumor Denikitug, Zimberelimab | GILD Gilead Sciences | Phase 1 | Active, not recruiting | 304 | Dec 2028 | Registry ↗ |
| Sep 16, 2026 | Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Ca… NCT07806773 · NSCLC, Non Small Cell Lung Cancer TUB-040 | GILD Gilead Sciences | Phase 2 | Not yet recruiting | 80 | May 2029 | Registry ↗ |
| Sep 11, 2026 | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors NCT06657222 · Advanced Solid Tumors, HNSCC TUB-030 | GILD Gilead Sciences | Phase 1/2 | Recruiting | 250 | Dec 2028 | Registry ↗ |
| Sep 11, 2026 | Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Coli… NCT06029972 · Ulcerative Colitis Tilpisertib Fosmecarbil, Placebo | GILD Gilead Sciences | Phase 2 | Active, not recruiting | 176 | Jan 2027 | Registry ↗ |
| Sep 11, 2026 | Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced o… NCT05186974 · Non-small Cell Lung Cancer Sacituzumab Govitecan-hziy (SG), Pembrolizumab | GILD Gilead Sciences | Phase 2 | Active, not recruiting | 193 | Mar 2027 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 11:24 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances